Update on Melasma—Part I: Pathogenesis Ana Cláudia C. EspósitoDaniel P. CassianoHélio Amante Miot Review Open access 29 July 2022 Pages: 1967 - 1988
Update on Melasma—Part II: Treatment Daniel P. CassianoAna Cláudia C. EspósitoEdiléia Bagatin Review Open access 29 July 2022 Pages: 1989 - 2012
A Review of Phase 3 Trials of Dupilumab for the Treatment of Atopic Dermatitis in Adults, Adolescents, and Children Aged 6 and Up Jennifer CatherMelodie YoungTayler Gonzalez Review Open access 26 August 2022 Pages: 2013 - 2038
Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments Anthony BewleyBernard HomeyAndrew Pink Review Open access 20 August 2022 Pages: 2039 - 2048
Randomized Clinical Trial of Conventional versus Indoor Daylight Photodynamic Therapy for Treatment of Actinic Cheilitis Mariachiara ArisiBenedetta GalliPierGiacomo Calzavara-Pinton Original Research Open access 30 July 2022 Pages: 2049 - 2061
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation Liudmila OdnopozovaAnton EdinAlkes Khotko Original Research Open access 02 August 2022 Pages: 2063 - 2075
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial Melinda J. GooderhamGiampiero GirolomoniGary Chan Original Research Open access 07 August 2022 Pages: 2077 - 2085
Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis April ArmstrongQian XiaLauren Seigel Original Research Open access 10 August 2022 Pages: 2087 - 2103
Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study Gaojie LiYuanxia GuWei Li Original Research Open access 11 August 2022 Pages: 2105 - 2115
Chronic Cutaneous Lupus Erythematosus in a White Population: Dermoscopic Characteristics by Clinical Subtype, Lesion Location and Disease Duration Magdalena ŻychowskaAdam Reich Original Research Open access 22 August 2022 Pages: 2117 - 2133
High Tolerability, Favorable Safety, and Subjects' Preference for a Single 200 mg/2 mL Tildrakizumab Injection: A Phase I, Open-Label, Randomized Crossover Trial in Healthy Volunteers Georgios KokolakisGerman KreisWiebke Sondermann Original Research Open access 19 August 2022 Pages: 2135 - 2144
Dupilumab Treatment of Atopic Dermatitis in Routine Clinical Care: Baseline Characteristics of Patients in the PROLEAD Prospective, Observational Study Diamant ThaçiAndrea BauerMatthias Augustin Original Research Open access 19 August 2022 Pages: 2145 - 2160
Pretreatment with an Aerosol Foam Containing Calcipotriene and Betamethasone Strongly Improves the Efficacy of Narrow-Band UVB Phototherapy Gaetano LicataMariachiara ArisiPiergiacomo Calzavara-Pinton Original Research Open access 26 August 2022 Pages: 2161 - 2171
Reassurance Techniques Do Not Significantly Impact Confidence in Biosimilars for Psoriasis: A Survey of a Convenience Sample of Individuals with Self-Identified Psoriasis Matthew L. HrinJeremy K. BraySteven R. Feldman Brief Report Open access 28 July 2022 Pages: 2173 - 2180
Efficacy of Calcipotriol/Betamethasone Dipropionate Fixed-Combination Aerosol Foam in the Treatment of Localized Scalp Psoriasis: A Real-Life Case Series from Switzerland Antonia RégnierRalph M. Trüeb Case Series Open access 20 August 2022 Pages: 2181 - 2188
Trifarotene 0.005% Cream in the Treatment of Facial and Truncal Acne Vulgaris in Patients with Skin of Color: a Case Series James Q. Del RossoEdward LainAndrew Alexis Case Series Open access 22 August 2022 Pages: 2189 - 2200